Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2010-08-02

AUTHORS

M A T Hildebrandt, J Gu, J Lin, Y Ye, W Tan, P Tamboli, C G Wood, X Wu

ABSTRACT

The long-term prognosis for clear cell renal cell carcinoma (ccRCC) is dramatically altered by the development of metastatic recurrence. However, there are very few indicators that can predict which patient will develop a recurrence. MicroRNAs regulate many cellular processes and have been shown to be associated with cancer development and recurrence. More recently it has been shown that microRNA genes can be epigenetically modified in cancer, resulting in aberrant silencing of microRNA genes with tumor suppressor functions. In this study, we show that two genes encoding for hsa-miR-9 are significantly hypermethylated in ccRCC tumors compared with adjacent normal tissues (P-value <0.001 for both miR-9-1 and miR-9-3) resulting in decreased expression, and that the methylation of these genes was more significant in DNA obtained from the primary tumor for patients who developed a recurrence (P-value: 0.012 and 0.009 for miR-9-1 and miR-9-3, respectively) than in tumors from nonrecurrent patients. Furthermore, methylation of miR-9-3 was significantly associated with an increased risk of recurrence (hazard ratio: 5.85, 95% confidence intervals: 1.30–26.35) and high methylation levels of either miR-9-1 or miR-9-3 resulted in a significant, nearly 30-month decrease in recurrence-free survival time (P-value: 0.034 and 0.007 for miR-9-1 and miR-9-3, respectively). Our results demonstrate that hsa-miR-9 is involved in the development of ccRCC while also having a role in the development of metastatic recurrence. More... »

PAGES

5724-5728

References to SciGraph publications

  • 2008-04-28. Potential role of miR-9 and miR-223 in recurrent ovarian cancer in MOLECULAR CANCER
  • 2009-06-16. Down-regulated miR-9 and miR-433 in human gastric carcinoma in JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/onc.2010.305

    DOI

    http://dx.doi.org/10.1038/onc.2010.305

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1033568112

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/20676129


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Carcinoma, Renal Cell", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "DNA Methylation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Kidney Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "MicroRNAs", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoplasm Invasiveness", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Polymerase Chain Reaction", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA", 
              "id": "http://www.grid.ac/institutes/grid.240145.6", 
              "name": [
                "Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hildebrandt", 
            "givenName": "M A T", 
            "id": "sg:person.0630636003.80", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630636003.80"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA", 
              "id": "http://www.grid.ac/institutes/grid.240145.6", 
              "name": [
                "Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Gu", 
            "givenName": "J", 
            "id": "sg:person.013531577452.52", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013531577452.52"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA", 
              "id": "http://www.grid.ac/institutes/grid.240145.6", 
              "name": [
                "Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lin", 
            "givenName": "J", 
            "id": "sg:person.014767221457.90", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014767221457.90"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA", 
              "id": "http://www.grid.ac/institutes/grid.240145.6", 
              "name": [
                "Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ye", 
            "givenName": "Y", 
            "id": "sg:person.016501611011.16", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016501611011.16"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA", 
              "id": "http://www.grid.ac/institutes/grid.240145.6", 
              "name": [
                "Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Tan", 
            "givenName": "W", 
            "id": "sg:person.01027513171.48", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01027513171.48"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA", 
              "id": "http://www.grid.ac/institutes/grid.240145.6", 
              "name": [
                "Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Tamboli", 
            "givenName": "P", 
            "id": "sg:person.01274763446.75", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01274763446.75"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA", 
              "id": "http://www.grid.ac/institutes/grid.240145.6", 
              "name": [
                "Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Wood", 
            "givenName": "C G", 
            "id": "sg:person.01040121722.56", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040121722.56"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA", 
              "id": "http://www.grid.ac/institutes/grid.240145.6", 
              "name": [
                "Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Wu", 
            "givenName": "X", 
            "id": "sg:person.014641373637.45", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014641373637.45"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1186/1476-4598-7-35", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040226229", 
              "https://doi.org/10.1186/1476-4598-7-35"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1756-9966-28-82", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035081058", 
              "https://doi.org/10.1186/1756-9966-28-82"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2010-08-02", 
        "datePublishedReg": "2010-08-02", 
        "description": "The long-term prognosis for clear cell renal cell carcinoma (ccRCC) is dramatically altered by the development of metastatic recurrence. However, there are very few indicators that can predict which patient will develop a recurrence. MicroRNAs regulate many cellular processes and have been shown to be associated with cancer development and recurrence. More recently it has been shown that microRNA genes can be epigenetically modified in cancer, resulting in aberrant silencing of microRNA genes with tumor suppressor functions. In this study, we show that two genes encoding for hsa-miR-9 are significantly hypermethylated in ccRCC tumors compared with adjacent normal tissues (P-value <0.001 for both miR-9-1 and miR-9-3) resulting in decreased expression, and that the methylation of these genes was more significant in DNA obtained from the primary tumor for patients who developed a recurrence (P-value: 0.012 and 0.009 for miR-9-1 and miR-9-3, respectively) than in tumors from nonrecurrent patients. Furthermore, methylation of miR-9-3 was significantly associated with an increased risk of recurrence (hazard ratio: 5.85, 95% confidence intervals: 1.30\u201326.35) and high methylation levels of either miR-9-1 or miR-9-3 resulted in a significant, nearly 30-month decrease in recurrence-free survival time (P-value: 0.034 and 0.007 for miR-9-1 and miR-9-3, respectively). Our results demonstrate that hsa-miR-9 is involved in the development of ccRCC while also having a role in the development of metastatic recurrence.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/onc.2010.305", 
        "isAccessibleForFree": false, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.2476518", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.2408774", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1097543", 
            "issn": [
              "0950-9232", 
              "1476-5594"
            ], 
            "name": "Oncogene", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "42", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "29"
          }
        ], 
        "keywords": [
          "clear cell renal cell carcinoma", 
          "cell renal cell carcinoma", 
          "renal cell carcinoma", 
          "metastatic recurrence", 
          "cell carcinoma", 
          "miR-9", 
          "cancer development", 
          "recurrence-free survival time", 
          "long-term prognosis", 
          "risk of recurrence", 
          "development of ccRCC", 
          "adjacent normal tissues", 
          "nonrecurrent patients", 
          "primary tumor", 
          "survival time", 
          "recurrence", 
          "patients", 
          "decreased expression", 
          "ccRCC tumors", 
          "normal tissues", 
          "tumor suppressor function", 
          "tumors", 
          "higher methylation levels", 
          "suppressor function", 
          "carcinoma", 
          "methylation status", 
          "methylation levels", 
          "aberrant silencing", 
          "prognosis", 
          "cancer", 
          "genes", 
          "risk", 
          "tissue", 
          "status", 
          "cellular processes", 
          "microRNAs", 
          "methylation", 
          "development", 
          "expression", 
          "levels", 
          "decrease", 
          "silencing", 
          "study", 
          "role", 
          "microRNA genes", 
          "DNA", 
          "indicators", 
          "function", 
          "time", 
          "results", 
          "process"
        ], 
        "name": "Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma", 
        "pagination": "5724-5728", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1033568112"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/onc.2010.305"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "20676129"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/onc.2010.305", 
          "https://app.dimensions.ai/details/publication/pub.1033568112"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-09-02T15:55", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_523.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/onc.2010.305"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/onc.2010.305'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/onc.2010.305'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/onc.2010.305'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/onc.2010.305'


     

    This table displays all metadata directly associated to this object as RDF triples.

    217 TRIPLES      21 PREDICATES      88 URIs      78 LITERALS      17 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/onc.2010.305 schema:about N0e7be2dec249495f907a4e319357f601
    2 N1958459be1ef43059bbfaaf2086a3c51
    3 N23e8194611c74a46b5ba3ec09654c9df
    4 N40768c8310ee4ed49777eccc97d31928
    5 N4cc6a9e133b74d5db8995ccf095bfd10
    6 N5a49ad3711ca40cf841a74866e94fe2a
    7 N606c17d8b6f74b56bc078d23d8d60a24
    8 Nc0042e0bc39f42ec9ba67aa430a60164
    9 Nc2cd37064cf54651b21f7dd3a75e2fb6
    10 Ne5d276dd9251496d94dcb7f844644b2f
    11 anzsrc-for:11
    12 anzsrc-for:1112
    13 schema:author N46868186dff142aca9e1f549e4590de5
    14 schema:citation sg:pub.10.1186/1476-4598-7-35
    15 sg:pub.10.1186/1756-9966-28-82
    16 schema:datePublished 2010-08-02
    17 schema:datePublishedReg 2010-08-02
    18 schema:description The long-term prognosis for clear cell renal cell carcinoma (ccRCC) is dramatically altered by the development of metastatic recurrence. However, there are very few indicators that can predict which patient will develop a recurrence. MicroRNAs regulate many cellular processes and have been shown to be associated with cancer development and recurrence. More recently it has been shown that microRNA genes can be epigenetically modified in cancer, resulting in aberrant silencing of microRNA genes with tumor suppressor functions. In this study, we show that two genes encoding for hsa-miR-9 are significantly hypermethylated in ccRCC tumors compared with adjacent normal tissues (P-value <0.001 for both miR-9-1 and miR-9-3) resulting in decreased expression, and that the methylation of these genes was more significant in DNA obtained from the primary tumor for patients who developed a recurrence (P-value: 0.012 and 0.009 for miR-9-1 and miR-9-3, respectively) than in tumors from nonrecurrent patients. Furthermore, methylation of miR-9-3 was significantly associated with an increased risk of recurrence (hazard ratio: 5.85, 95% confidence intervals: 1.30–26.35) and high methylation levels of either miR-9-1 or miR-9-3 resulted in a significant, nearly 30-month decrease in recurrence-free survival time (P-value: 0.034 and 0.007 for miR-9-1 and miR-9-3, respectively). Our results demonstrate that hsa-miR-9 is involved in the development of ccRCC while also having a role in the development of metastatic recurrence.
    19 schema:genre article
    20 schema:isAccessibleForFree false
    21 schema:isPartOf Na7a9074938af4dac9dd08204c2e09a45
    22 Nf4bea3ce3c1a4105b0e2e848534c9c23
    23 sg:journal.1097543
    24 schema:keywords DNA
    25 aberrant silencing
    26 adjacent normal tissues
    27 cancer
    28 cancer development
    29 carcinoma
    30 ccRCC tumors
    31 cell carcinoma
    32 cell renal cell carcinoma
    33 cellular processes
    34 clear cell renal cell carcinoma
    35 decrease
    36 decreased expression
    37 development
    38 development of ccRCC
    39 expression
    40 function
    41 genes
    42 higher methylation levels
    43 indicators
    44 levels
    45 long-term prognosis
    46 metastatic recurrence
    47 methylation
    48 methylation levels
    49 methylation status
    50 miR-9
    51 microRNA genes
    52 microRNAs
    53 nonrecurrent patients
    54 normal tissues
    55 patients
    56 primary tumor
    57 process
    58 prognosis
    59 recurrence
    60 recurrence-free survival time
    61 renal cell carcinoma
    62 results
    63 risk
    64 risk of recurrence
    65 role
    66 silencing
    67 status
    68 study
    69 suppressor function
    70 survival time
    71 time
    72 tissue
    73 tumor suppressor function
    74 tumors
    75 schema:name Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma
    76 schema:pagination 5724-5728
    77 schema:productId N4cea73d90b2f4da19212db0f69ee304c
    78 Nb3913558e5f546218d92e260321b1638
    79 Nb99351a763924aca9b9af6182dd63bc4
    80 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033568112
    81 https://doi.org/10.1038/onc.2010.305
    82 schema:sdDatePublished 2022-09-02T15:55
    83 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    84 schema:sdPublisher N98efed4cf7c2444b8a6c611ae272290f
    85 schema:url https://doi.org/10.1038/onc.2010.305
    86 sgo:license sg:explorer/license/
    87 sgo:sdDataset articles
    88 rdf:type schema:ScholarlyArticle
    89 N0936dc86cb8b4e6e8eb3f22e8857c4d1 rdf:first sg:person.016501611011.16
    90 rdf:rest N3e77b7288a9e4e9583f129960c823deb
    91 N0e7be2dec249495f907a4e319357f601 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    92 schema:name Kidney Neoplasms
    93 rdf:type schema:DefinedTerm
    94 N1958459be1ef43059bbfaaf2086a3c51 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    95 schema:name Male
    96 rdf:type schema:DefinedTerm
    97 N23e8194611c74a46b5ba3ec09654c9df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    98 schema:name Carcinoma, Renal Cell
    99 rdf:type schema:DefinedTerm
    100 N2b1ce97608bb4400b4f2fbf03ec401b6 rdf:first sg:person.013531577452.52
    101 rdf:rest Ne220b35bdf574c5eb349cd91554a2c27
    102 N3e77b7288a9e4e9583f129960c823deb rdf:first sg:person.01027513171.48
    103 rdf:rest N7c7abe617a3048eab6a67438af169a39
    104 N40768c8310ee4ed49777eccc97d31928 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    105 schema:name Neoplasm Invasiveness
    106 rdf:type schema:DefinedTerm
    107 N46868186dff142aca9e1f549e4590de5 rdf:first sg:person.0630636003.80
    108 rdf:rest N2b1ce97608bb4400b4f2fbf03ec401b6
    109 N4cc6a9e133b74d5db8995ccf095bfd10 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    110 schema:name Humans
    111 rdf:type schema:DefinedTerm
    112 N4cea73d90b2f4da19212db0f69ee304c schema:name doi
    113 schema:value 10.1038/onc.2010.305
    114 rdf:type schema:PropertyValue
    115 N5a49ad3711ca40cf841a74866e94fe2a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    116 schema:name Middle Aged
    117 rdf:type schema:DefinedTerm
    118 N606c17d8b6f74b56bc078d23d8d60a24 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    119 schema:name Polymerase Chain Reaction
    120 rdf:type schema:DefinedTerm
    121 N7c7abe617a3048eab6a67438af169a39 rdf:first sg:person.01274763446.75
    122 rdf:rest Nba02a4a6dd164d0d932cafe047240b38
    123 N98efed4cf7c2444b8a6c611ae272290f schema:name Springer Nature - SN SciGraph project
    124 rdf:type schema:Organization
    125 Na7a9074938af4dac9dd08204c2e09a45 schema:issueNumber 42
    126 rdf:type schema:PublicationIssue
    127 Nab5fa2a817334b8c918fec5e364346cf rdf:first sg:person.014641373637.45
    128 rdf:rest rdf:nil
    129 Nb3913558e5f546218d92e260321b1638 schema:name dimensions_id
    130 schema:value pub.1033568112
    131 rdf:type schema:PropertyValue
    132 Nb99351a763924aca9b9af6182dd63bc4 schema:name pubmed_id
    133 schema:value 20676129
    134 rdf:type schema:PropertyValue
    135 Nba02a4a6dd164d0d932cafe047240b38 rdf:first sg:person.01040121722.56
    136 rdf:rest Nab5fa2a817334b8c918fec5e364346cf
    137 Nc0042e0bc39f42ec9ba67aa430a60164 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    138 schema:name MicroRNAs
    139 rdf:type schema:DefinedTerm
    140 Nc2cd37064cf54651b21f7dd3a75e2fb6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    141 schema:name Female
    142 rdf:type schema:DefinedTerm
    143 Ne220b35bdf574c5eb349cd91554a2c27 rdf:first sg:person.014767221457.90
    144 rdf:rest N0936dc86cb8b4e6e8eb3f22e8857c4d1
    145 Ne5d276dd9251496d94dcb7f844644b2f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    146 schema:name DNA Methylation
    147 rdf:type schema:DefinedTerm
    148 Nf4bea3ce3c1a4105b0e2e848534c9c23 schema:volumeNumber 29
    149 rdf:type schema:PublicationVolume
    150 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    151 schema:name Medical and Health Sciences
    152 rdf:type schema:DefinedTerm
    153 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    154 schema:name Oncology and Carcinogenesis
    155 rdf:type schema:DefinedTerm
    156 sg:grant.2408774 http://pending.schema.org/fundedItem sg:pub.10.1038/onc.2010.305
    157 rdf:type schema:MonetaryGrant
    158 sg:grant.2476518 http://pending.schema.org/fundedItem sg:pub.10.1038/onc.2010.305
    159 rdf:type schema:MonetaryGrant
    160 sg:journal.1097543 schema:issn 0950-9232
    161 1476-5594
    162 schema:name Oncogene
    163 schema:publisher Springer Nature
    164 rdf:type schema:Periodical
    165 sg:person.01027513171.48 schema:affiliation grid-institutes:grid.240145.6
    166 schema:familyName Tan
    167 schema:givenName W
    168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01027513171.48
    169 rdf:type schema:Person
    170 sg:person.01040121722.56 schema:affiliation grid-institutes:grid.240145.6
    171 schema:familyName Wood
    172 schema:givenName C G
    173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040121722.56
    174 rdf:type schema:Person
    175 sg:person.01274763446.75 schema:affiliation grid-institutes:grid.240145.6
    176 schema:familyName Tamboli
    177 schema:givenName P
    178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01274763446.75
    179 rdf:type schema:Person
    180 sg:person.013531577452.52 schema:affiliation grid-institutes:grid.240145.6
    181 schema:familyName Gu
    182 schema:givenName J
    183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013531577452.52
    184 rdf:type schema:Person
    185 sg:person.014641373637.45 schema:affiliation grid-institutes:grid.240145.6
    186 schema:familyName Wu
    187 schema:givenName X
    188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014641373637.45
    189 rdf:type schema:Person
    190 sg:person.014767221457.90 schema:affiliation grid-institutes:grid.240145.6
    191 schema:familyName Lin
    192 schema:givenName J
    193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014767221457.90
    194 rdf:type schema:Person
    195 sg:person.016501611011.16 schema:affiliation grid-institutes:grid.240145.6
    196 schema:familyName Ye
    197 schema:givenName Y
    198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016501611011.16
    199 rdf:type schema:Person
    200 sg:person.0630636003.80 schema:affiliation grid-institutes:grid.240145.6
    201 schema:familyName Hildebrandt
    202 schema:givenName M A T
    203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630636003.80
    204 rdf:type schema:Person
    205 sg:pub.10.1186/1476-4598-7-35 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040226229
    206 https://doi.org/10.1186/1476-4598-7-35
    207 rdf:type schema:CreativeWork
    208 sg:pub.10.1186/1756-9966-28-82 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035081058
    209 https://doi.org/10.1186/1756-9966-28-82
    210 rdf:type schema:CreativeWork
    211 grid-institutes:grid.240145.6 schema:alternateName Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    212 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    213 Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    214 schema:name Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    215 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    216 Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    217 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...